A new study shows that sequencing tumor DNA in ascites, pleural fluid, cerebrospinal fluid, and pericardial effusions can ...
A case report in the Journal of Neurology documents systemic and central nervous system hypofucosylation in a child with ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented interim Phase I/II data for ARO-MAPT, an investigational small interfering ...
Clinical Trials Arena on MSN
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients.
IDWeek presentations highlight Delve Detect’s impact on clinical diagnosis, treatment, and management of patients with challenging infections. Delve Bio, Inc., a UCSF spin-out and pioneer in ...
ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers . Arrowhead’s TRiM™ platform ...
Practical framework helps researchers select optimal assay platforms amid limited sample volume,low-abundance targets,instrument constraints and budget pressure HUSTON, TX, UNITED STATES, October 14, ...
Nucleic acid therapeutics, such as antisense oligonucleotides (ASOs), have emerged as promising platforms for treating a ...
Moldovan 1st Divison CSF Balti Politehnica Chisinau live score and match summary are on Yeni Şafak Sports. Probable lineups for CSF Balti Politehnica Chisinau match, goals in the match, and the final ...
IntroductionIn recent years, information security has come to be viewed not just as an IT department issue, but as a ...
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration ...
A research team has developed a highly sensitive electrochemical biosensor capable of rapidly and accurately diagnosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results